GlassScriptPhysician profile
Jed Padre
NPI 1285169110
$9,385.73
in general payments reported to CMS, 2019-2025
25 companies · $1,246 in 2025
The $1,246 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $585 · 2021: $2,767 · 2022: $1,763 · 2023: $1,321 · 2024: $1,704 · 2025: $1,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,203 · Education: $68.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,203.33 |
| Education | $68.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,112.77 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $1,471.94 | 2020-2024 | Xarelto |
| Novo Nordisk INC | $1,118.23 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $1,100.25 | 2021-2025 | |
| Lilly USA, LLC | $786.57 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $570.44 | 2021-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $418.24 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $368.50 | 2020-2025 | Trelegy Ellipta |
| Amarin Pharma, INC. | $221.65 | 2020-2022 | |
| Esperion Therapeutics, INC. | $192.37 | 2021 | |
| Novartis Pharmaceuticals Corporation | $164.42 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $150.30 | 2020-2024 | Verquvo |
| Sumitomo Pharma America, INC. | $147.35 | 2023-2025 | Gemtesa |
| Pfizer INC. | $97.45 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $93.73 | 2022-2024 | Eliquis |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $72.74 | 2024-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $61.43 | 2024-2025 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $52.78 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $43.25 | 2025 | Rexulti |
| Arbor Pharmaceuticals, INC. | $33.78 | 2020-2021 | |
| Hologic Sales and Service, LLC | $23.48 | 2025 | Aptima, Thinprep 2000 Processor |
| Dexcom, INC. | $22.50 | 2024 | Dexcom G6 Transmitter |
| Genentech USA, INC. | $21.46 | 2021 | |
| Shield Therapeutics INC | $20.68 | 2024 | |
| Eisai INC. | $19.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jed Padre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.